Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of etanercept safety and efficacy in psoriatic arthritis
ChiCTR1900027001Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Nov 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of etanercept in psoriatic arthritis (PsA), sponsored by First Hospital of China Medical University. Primary endpoint: Psoriasis Area and Severity Index. Planned start Nov 2019; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ChiCTR1900027001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027001.